Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trialJoël Guigay, Keun-Wook Lee, Manish R Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX studyAlain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
Joint Bone Spine|October 24, 2024
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational studyAlexandra Ladouceur, Thomas Barnetche, Sorilla Prey, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Léa Rouxel, Thomas Barnetche, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Eleonora Mauric, Alice Tison, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.
RMD Open|November 29, 2023
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational studyAlexandra Ladouceur, Thomas Barnetche, Gael Mouterde, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2021
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trialRachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, et al.
Pageof 5